This company has been marked as potentially delisted and may not be actively trading. Digirad (DRAD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock DRAD vs. NRXS, VRAYQ, VIVE, ELMD, QTI, GBIO, ECOR, EGRX, MODD, and NEPHShould you be buying Digirad stock or one of its competitors? The main competitors of Digirad include NeurAxis (NRXS), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), QT Imaging (QTI), Generation Bio (GBIO), electroCore (ECOR), Eagle Pharmaceuticals (EGRX), Modular Medical (MODD), and Nephros (NEPH). These companies are all part of the "medical" sector. Digirad vs. Its Competitors NeurAxis ViewRay Viveve Medical Electromed QT Imaging Generation Bio electroCore Eagle Pharmaceuticals Modular Medical Nephros Digirad (NASDAQ:DRAD) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Do institutionals & insiders have more ownership in DRAD or NRXS? 11.4% of Digirad shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 12.5% of Digirad shares are owned by company insiders. Comparatively, 15.2% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer DRAD or NRXS? In the previous week, NeurAxis had 1 more articles in the media than Digirad. MarketBeat recorded 1 mentions for NeurAxis and 0 mentions for Digirad. Digirad's average media sentiment score of 0.00 beat NeurAxis' score of -1.00 indicating that Digirad is being referred to more favorably in the media. Company Overall Sentiment Digirad Neutral NeurAxis Negative Do analysts recommend DRAD or NRXS? NeurAxis has a consensus target price of $7.00, suggesting a potential upside of 188.66%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Digirad.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Digirad 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DRAD or NRXS more profitable? Digirad has a net margin of -5.32% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Digirad's return on equity.Company Net Margins Return on Equity Return on Assets Digirad-5.32% -3.75% -0.85% NeurAxis -492.76%N/A -641.25% Which has preferable earnings and valuation, DRAD or NRXS? Digirad has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Digirad, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDigirad$114.18M0.00-$4.63M-$0.35N/ANeurAxis$3.22M7.44-$14.63M-$0.99-2.45 Which has more volatility & risk, DRAD or NRXS? Digirad has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500. SummaryNeurAxis beats Digirad on 8 of the 15 factors compared between the two stocks. Get Digirad News Delivered to You Automatically Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRAD vs. The Competition Export to ExcelMetricDigiradElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.14M$43.73M$5.79B$10.15BDividend Yield83.65%N/A5.69%4.60%P/E Ratio-0.683.9974.5925.92Price / SalesN/A221.57453.5485.33Price / Cash0.6941.3637.0859.91Price / BookN/A2.4512.156.29Net Income-$4.63M-$2.66M$3.28B$270.77M Digirad Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRADDigiradN/AN/AN/A-48.9%$10.14M$114.18M-0.68618High Trading VolumeNRXSNeurAxis2.0116 of 5 stars$2.63+3.5%$7.00+166.2%-21.9%$25.93M$3.22M-1.4319Negative NewsShort Interest ↑Gap UpVRAYQViewRayN/A$0.00+∞N/AN/A$18K$102.21M0.00300Gap UpHigh Trading VolumeVIVEViveve MedicalN/A$0.00flatN/AN/A$1K$6.83M0.0070ELMDElectromed3.9083 of 5 stars$23.95-3.2%$36.25+51.4%+42.1%$206.48M$64M31.93160QTIQT ImagingN/A$2.52+3.3%N/A+316.7%$68.38M$4.00M0.00N/AGBIOGeneration Bio4.1268 of 5 stars$5.98-0.3%$10.67+78.4%-75.4%$40.41M$19.89M-0.55150Positive NewsShort Interest ↓ECORelectroCore2.2309 of 5 stars$5.26-0.9%$25.50+384.8%-16.6%$40.27M$25.18M-3.2550Positive NewsEGRXEagle PharmaceuticalsN/A$3.10+0.2%N/A-14.2%$40.20M$257.55M0.00100Gap DownMODDModular Medical1.2657 of 5 stars$0.70-2.6%N/A-66.7%$39.95MN/A-1.3820News CoverageGap UpNEPHNephros3.2109 of 5 stars$4.20+12.6%$5.50+31.0%+123.3%$39.54M$14.16M35.0030Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies NeurAxis Competitors ViewRay Competitors Viveve Medical Competitors Electromed Competitors QT Imaging Competitors Generation Bio Competitors electroCore Competitors Eagle Pharmaceuticals Competitors Modular Medical Competitors Nephros Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRAD) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Digirad Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Digirad With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRAD Stock Alerts